

BLA 761082

CORRECTED BLA APPROVAL

Kashiv BioSciences, LLC
Attention: John Pakulski
Senior VP, Global Regulatory Affairs
20 New England Avenue
Piscataway, NJ 08854

Dear Mr. Pakulski:

Please refer to your biologics license application (BLA) dated July 8, 2017, received July 10, 2017, and your amendments, submitted under section 351(k) of the Public Health Service Act for Releuko (filgrastim-ayow) injection.

We also refer to our approval letter dated February 25, 2022, which contained the following error:

Incorrectly stated that packaging is performed at [REDACTED] (b) (4)
[REDACTED] The drug product (DP) vial is labeled and packaged at Kashiv BioSciences LLC, Chicago, IL. The pre-filled syringe (PFS) is labeled at Kashiv BioSciences LLC, Chicago, IL and packaged at [REDACTED] (b) (4)
[REDACTED]

This corrected action letter incorporates the correction of the errors. The effective action date will remain February 25, 2022, the date of the original letter.

We acknowledge receipt of your resubmission dated August 27, 2021, which constituted a complete response to our August 2, 2021, action letter.

LICENSING

We are issuing Department of Health and Human Services U.S. License No. 2131 to Kashiv BioSciences, LLC, Piscataway, NJ, under the provisions of section 351(k) of the Public Health Service Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Releuko (filgrastim-ayow). Releuko is indicated for:

- Decrease the incidence of infection, as manifested by febrile neutropenia, in

patients with nonmyeloid malignancies receiving myelosuppressive anti- cancer drugs associated with a significant incidence of severe neutropenia with fever.

- Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML).
- Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).
- Reduce the incidence and duration of sequelae of severe neutropenia, (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture filgrastim-ayow drug substance at Kashiv Biosciences LLC DS manufacturing facility in Chicago, Illinois. The final formulated DP will be manufactured and filled at (b) (4)

(b) (4) The DP vial is labeled and packaged at Kashiv BioSciences LLC, Chicago, IL. The PFS is labeled at Kashiv BioSciences LLC, Chicago, IL and packaged at

(b) (4) You may label your product with the proprietary name, Releuko, and market it in 300 mcg/mL and 480 mcg/1.6 mL in a single-dose vial as well as 300 mcg/0.5 mL and 480 mcg/0.8 mL in a single-dose prefilled syringe.

DATING PERIOD

The dating period for Releuko shall be 24 months from the date of manufacture when stored at 2°C -8 °C. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be (b) (4) months from the date of manufacture when stored at (b) (4) °C.

FDA LOT RELEASE

You are not currently required to submit samples of future lots of Releuko to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of Releuko, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

WAIVER OF ½ PAGE LENGTH REQUIREMENT FOR HIGHLIGHTS

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of Prescribing Information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Patient Package Insert, and Instructions for Use). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As (October 2009)*.²

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761082.**” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for

¹ See <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

This product is appropriately labeled for use in all relevant pediatric populations. Therefore, no additional pediatric studies are needed at this time.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitments:

4226-1 To perform a study to evaluate the impact of the removal of kanamycin from the (b) (4) drug substance manufacturing process. If the data support removal of kanamycin, a plan for the removal of kanamycin from the manufacturing process will be provided. The plan should include an evaluation of consistency of the fermentation process and comparability of the (b) (4) drug substance manufactured with and without kanamycin. The results will be reported per 21 CFR 601.12.

The timetable you submitted on February 7, 2022, states that you will conduct this study according to the following schedule:

Final Report Submission: 12/31/2024

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80).

³ For the most recent version of a guidance, check the FDA guidance web page at <https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

Prominently identify all adverse experience reports as described in 21 CFR 600.80.

You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

If you have any questions, contact Courtney Hamilton, Regulatory Project Manager at 301-796-6849 or at Courtney.Hamilton@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Ann Farrell, MD
Director
Division of Nonmalignant Hematology
Office of Cardiology, Hematology,
Endocrinology, and Nephrology
Center for Drug Evaluation and Research

ENCLOSURES:

- Content of Labeling
 - Prescribing Information
 - Patient Package Insert
 - Instructions for Use
- Carton and Container Labeling

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ANN T FARRELL
11/15/2022 02:52:39 PM